Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
<p>Abstract</p> <p>Background</p> <p>The proteasome inhibitor bortezomib can inhibit activation of the transcription factor NF-κB, a mechanism implicated in its anti-neoplastic effects observed in mantle cell lymphoma (MCL). However, NF-κB can be activated through many...
Päätekijät: | , , , , |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | English |
Julkaistu: |
BMC
2008-05-01
|
Sarja: | Molecular Cancer |
Linkit: | http://www.molecular-cancer.com/content/7/1/40 |